Translating advances in schizophrenia treatment: a glass ceiling

Patrick D McGorry
Med J Aust 2003; 178 (9): . || doi: 10.5694/j.1326-5377.2003.tb05282.x
Published online: 5 May 2003

Reforms to the management of schizophrenia in Australia have stalled

A decade ago, the management of schizophrenia languished in medicine's backwaters. Treatment still occurred in asylums, using drug therapies serendipitously discovered decades earlier. Even these had proved ultimately disappointing and were used in excessive doses, with inevitable serious adverse effects, a great deal of suffering and only modest benefit. Psychosocial treatments were similarly obsolete or simplistic, with a weak evidence base. Therapeutic nihilism was pervasive and stigma profound. The public knew little about schizophrenia and gave little thought to it unless they happened to be directly touched by the disorder in their own lives. The Burdekin Report graphically captured this bleak scenario.1

  • Patrick D McGorry

  • Department of Psychiatry, University of Melbourne, Parkville, VIC.


Competing interests:

The author has received unrestricted research grant support for investigator-initiated trials and/or acted as a consultant to Novartis, Janssen-Cilag, Sanofi-Synthélabo, Eli Lilly, Mayne Pharma, Lundbeck and AstraZeneca.


remove_circle_outline Delete Author
add_circle_outline Add Author

Do you have any competing interests to declare? *

I/we agree to assign copyright to the Medical Journal of Australia and agree to the Conditions of publication *
I/we agree to the Terms of use of the Medical Journal of Australia *
Email me when people comment on this article

Responses are now closed for this article.